Author

C. E. Willoughby

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1 Organism:mouse· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Collins· 1 shared A. Filby· 1 shared A. Fuller· 1 shared A. Hedley· 1 shared A. J. MacFalane· 1 shared C. A. Ford· 1 shared C. Andreu-Oller· 1 shared C. Fan· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Collins

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Small RNA Sequencing Reveals a Distinct MicroRNA Signature between Glucocorticoid Responder and Glucocorticoid Non-responder Primary Human Trabecular Meshwork Cells after Dexamethasone Treatment

K. Kandasamy, X. Fan, R. Haribalaganesh, D. Bharanidharan, R. Sharmila, R. Krishnadas, V. Muthukkaruppan, C. E. Willoughby, S. Srinivasan

bioRxiv · Jun 19, 2023Cell Biology

CXCR2 inhibition enables NASH-HCC immunotherapy

J. Leslie, J. B. G. Mackey, T. Jamieson, E. Ramon-Gil, T. M. Drake, F. Fercoq, W. Clark, K. Gilroy, A. Hedley, C. Nixon, S. Luli, M. Laszczewska, R. Pinyol, R. Esteban-Fabro, C. E. Willoughby, , Carlin

This study shows that combining CXCR2 inhibition with anti-PD1 therapy enhances immunotherapy response in NASH-HCC by reprogramming tumor-associated neutrophils.

bioRxiv · Feb 24, 2022Cancer Biology